- Conditions
- Hereditary Spastic Paraplegia Type 50
- Interventions
- MELPIDA
- Genetic
- Lead sponsor
- Elpida Therapeutics SPC
- Industry
- Eligibility
- 4 Months to 72 Months
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced May 22, 2026, 12:37 AM EDT